Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Conlon

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectorsRenius Owen, Ronald J Mandel, Chandramohan V Ammini, et al.
Human Gene Therapy|January 18, 2006
Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vectorThomas J Conlon, Glenn Walter, Renius Owen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2005
Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vectorThomas J Conlon, Travis Cossette, Kirsten Erger, et al.
Journal of Inherited Metabolic Disease|May 27, 2018
Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaYoung Mok Lee, Thomas J Conlon, Andrew Specht, et al.
Human Gene Therapy|November 13, 2012
Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1Shilpa Prabhakar, Mehran Taherian, Davide Gianni, et al.
Circulation Research|July 29, 2006
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivoChristina A Pacak, Cathryn S Mah, Bijoy D Thattaliyath, et al.
Human Gene Therapy Methods|June 15, 2012
Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9Mai K ElMallah, Darin J Falk, Michael A Lane, et al.
Human Gene Therapy. Clinical Development|September 12, 2013
Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidaseThomas J Conlon, Kirsten Erger, Stacy Porvasnik, et al.
Human Gene Therapy. Clinical Development|September 22, 2015
Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical PlanningManuela Corti, Brian Cleaver, Nathalie Clément, et al.
Human Gene Therapy|June 17, 2015
Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis PigmentosaWen-Tao Deng, Frank M Dyka, Astra Dinculescu, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectorsRenius Owen, Ronald J Mandel, Chandramohan V Ammini, et al.
Human Gene Therapy|January 18, 2006
Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vectorThomas J Conlon, Glenn Walter, Renius Owen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2005
Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vectorThomas J Conlon, Travis Cossette, Kirsten Erger, et al.
Journal of Inherited Metabolic Disease|May 27, 2018
Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaYoung Mok Lee, Thomas J Conlon, Andrew Specht, et al.
Human Gene Therapy|November 13, 2012
Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1Shilpa Prabhakar, Mehran Taherian, Davide Gianni, et al.
Circulation Research|July 29, 2006
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivoChristina A Pacak, Cathryn S Mah, Bijoy D Thattaliyath, et al.
Human Gene Therapy Methods|June 15, 2012
Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9Mai K ElMallah, Darin J Falk, Michael A Lane, et al.
Human Gene Therapy. Clinical Development|September 12, 2013
Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidaseThomas J Conlon, Kirsten Erger, Stacy Porvasnik, et al.
Human Gene Therapy. Clinical Development|September 22, 2015
Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical PlanningManuela Corti, Brian Cleaver, Nathalie Clément, et al.
Human Gene Therapy|June 17, 2015
Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis PigmentosaWen-Tao Deng, Frank M Dyka, Astra Dinculescu, et al.
Pageof 5